蒲地蓝消炎口服液联合西药治疗上呼吸道感染的疗效观察

Observation on Efficacy of Pudilan Oral Liquid Combined with Western Medicine in Treatment of Upper Respiratory Tract Infection

目的:探讨蒲地蓝消炎口服液联合西药治疗上呼吸道感染的临床疗效。方法:选取2016年2月至2017年4月肇庆市第一人民医院收治的上呼吸道感染患者104例,以随机数字表法分为对照组和观察组,每组52例。对照组患者在常规对症治疗后静脉滴注头孢呋辛钠或利巴韦林注射液治疗,观察组患者在对照组的基础上加用蒲地蓝消炎口服液。观察两组患者的临床疗效、完全退热时间、上呼吸道卡他症状缓解时间、超敏C反应蛋白(hs-CRP)水平、肿瘤坏死因子(TNF-α)水平及不良反应发生情况。结果:观察组患者的总有效率为96.15%(50/52),明显高于对照组的82.69%(43/52),差异有统计学意义(P<0.05);观察组患者平均完全退热时间和上呼吸道卡他症状缓解时间分别为(47.30±4.61)、(50.42±7.23) h,明显短于对照组的(69.54±5.73)、(70.49±4.47) h,差异均有统计学意义(P<0.05);治疗后,两组患者hs-CRP、TNF-α水平较治疗前明显降低,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05);观察组、对照组患者不良反应发生率分别为7.69%(4/52)、5.77%(3/52),差异无统计学意义(P>0.05)。结论:蒲地蓝消炎口服液联合西药治疗上呼吸道感染的疗效显著,能快速缓解症状,减轻炎症反应,且安全性高。

OBJECTIVE:To explore the clinical efficacy of Pudilan oral liquid combined with western medicine in treatment of upper respiratory tract infection. METHODS:104 patients with upper respiratory tract infection admitted into Zhaoqing the First People’s Hospital from Feb. 2016 to Apr. 2017 were extracted to be divided into the observation group and the control group via the random number table, with 52 cases in each. Patients in the control group were treated with the intravenous cefuroxime sodium or ribavirin injection after routine symptomatic treatment, the observation group received Pudilan oral liquid on the basis of the control group. The clinical efficacy, complete antipyretic time, remission time of upper respiratory tract cataract symptoms, hypersensitive c-reactive protein(hs-CRP), tumor necrosis factor(TNF-α) levels and adverse drug reactions of two groups were observed. RESULTS:The total effective rate of observation group was 96.15%(50/52), significantly higher than that of control group(82.69%, 43/52), the difference was statistically significant(P<0.05). In the observation group, the average complete antipyretic time and remission time of upper respiratory tract cataract symptoms were(47.30±4.61) and(50.42±7.23) h, respectively, which were significantly shorter than those in the control group [(69.54±5.73) and(70.49±4.47) h], and the differences were statistically significant(P<0.05). After treatment, the levels of hs-CRP and TNF-α in the groups were significantly lower than those before treatment, and the observation group were significantly lower than the control group, with statistically significant differences(P<0.05). The incidence of adverse drug reactions in observation group and control group were 7.69%(4/52) and 5.77%(3/52), respectively, and the difference was not statistically significant(P>0.05). CONCLUSIONS:The efficacy of Pudilan oral liquid combined with western medicine in treatment of upper respiratory tract infection is significant, which can quickly relieve the symptoms and reduce the inflammation with higher safety.